ARDX
Bearish signalScored 2026-08-27 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Ardelyx, Inc.
- Nom
- Ardelyx, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $753.8M
- Employés
- 489
- PDG
- Michael G. Raab
- Site web
- https://www.ardelyx.com
- Marché
- AKBADMACMAZEXERS
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 100 242 titres (~436 837,48 $ US)
- Insiders
- RAAB MICHAEL
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$168,878
Avg sell (VWAP, 90d window) $3.86 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-21 | Bishop John E | Sell · S | 2,469 | $3.86 | $9,523 | Form 4 |
| 2026-08-21 | Brady James Parker | Sell · S | 13,160 | $3.86 | $50,757 | Form 4 |
| 2026-08-21 | Foster Eric Duane | Sell · S | 2,575 | $3.86 | $9,932 | Form 4 |
| 2026-08-21 | Hohenleitner Susan | Sell · S | 1,558 | $3.86 | $6,009 | Form 4 |
| 2026-08-21 | Kelliher Mike | Sell · S | 2,002 | $3.86 | $7,722 | Form 4 |
| 2026-08-21 | RAAB MICHAEL | Sell · S | 19,178 | $3.86 | $73,968 | Form 4 |
| 2026-08-21 | Reilly Joseph James | Sell · S | 1,110 | $3.86 | $4,281 | Form 4 |
| 2026-08-21 | Williams Laura A | Sell · S | 1,734 | $3.86 | $6,688 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-08-27 Drivers: fundamentals. Moteurs : fondamentaux.
ARDX presents a deeply unfavorable risk profile: a weak catalyst score of 10 driven by a guidance cut, an 18% stock collapse, and active securities investigations leave no credible near-term upside catalyst.
The first sentence of the analysis written for ARDX on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.31 · operating margin -10% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 89.5% | 84.8% | 85.7% | 92.1% | 90.1% | |
| Ebit Margin | -7.9% | -5.6% | -45.5% | -119.1% | -1521.8% | |
| Ebitda Margin | -7.2% | -5.0% | -44.5% | -116.9% | -1494.0% | |
| Operating Profit Margin | -10.1% | -8.4% | -50.8% | -122.2% | -1528.6% | |
| Pretax Profit Margin | -14.9% | -11.7% | -52.6% | -128.8% | -1566.4% | |
| Continuous Operations Profit Margin | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% | |
| Net Profit Margin | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% | |
| Bottom Line Profit Margin | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% | |
| Current Ratio | 4.315 | 4.580 | 4.884 | 2.341 | 2.530 | |
| Quick Ratio | 4.115 | 4.308 | 4.637 | 2.291 | 2.530 | |
| Solvency Ratio | -0.175 | -0.141 | -0.495 | -0.720 | -2.309 | |
| Cash Ratio | 0.767 | 0.834 | 0.426 | 1.465 | 1.371 | |
| Price To Earnings Ratio | -22.423 | -29.824 | -20.667 | -6.786 | -0.724 | |
| Price To Earnings Growth Ratio | -0.424 | 0.688 | 0.723 | 0.094 | -0.016 | |
| Forward Price To Earnings Growth Ratio | -0.424 | 0.688 | 0.723 | 0.094 | -0.016 | |
| Price To Earnings Diluted Ratio | -22.423 | -29.824 | -20.667 | -6.786 | -0.724 | |
| Price To Earnings Diluted Growth Ratio | -0.424 | 0.688 | 0.723 | 0.094 | -0.016 | |
| Price To Book Ratio | 8.417 | 6.882 | 8.152 | 4.600 | 1.387 | |
| Price To Sales Ratio | 3.450 | 3.575 | 10.926 | 8.671 | 11.353 | |
| Price To Free Cash Flow Ratio | -31.955 | -26.029 | -15.099 | -6.452 | -0.742 | |
| Price To Operating Cash Flow Ratio | -33.077 | -26.616 | -15.157 | -6.457 | -0.751 | |
| Debt To Assets Ratio | 0.422 | 0.352 | 0.188 | 0.192 | 0.304 | |
| Debt To Equity Ratio | 1.267 | 0.885 | 0.336 | 0.371 | 0.551 | |
| Debt To Capital Ratio | 0.559 | 0.470 | 0.251 | 0.270 | 0.355 | |
| Long Term Debt To Capital Ratio | 0.553 | 0.465 | 0.230 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.005 | 2.515 | 1.784 | 1.933 | 1.815 | |
| Working Capital Turnover Ratio | 1.423 | 1.407 | 0.877 | 0.618 | 0.082 | |
| Operating Cash Flow Ratio | -0.479 | -0.576 | -1.780 | -1.068 | -2.888 | |
| Operating Cash Flow Sales Ratio | -0.104 | -0.134 | -0.721 | -1.343 | -15.109 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | 1.023 | 1.004 | 1.001 | 1.012 | |
| Debt Service Coverage Ratio | -1.009 | -0.845 | -6.299 | -1.919 | -4.103 | |
| Interest Coverage Ratio | -1.443 | -1.391 | -7.130 | -12.568 | -34.284 | |
| Short Term Operating Cash Flow Coverage Ratio | -28.724 | 0.000 | 0.000 | -2.622 | -4.728 | |
| Operating Cash Flow Coverage Ratio | -0.201 | -0.292 | -1.603 | -1.921 | -3.352 | |
| Capital Expenditure Coverage Ratio | -28.474 | -44.321 | -260.805 | -1,273.527 | -81.709 | |
| Dividend Paid And Capex Coverage Ratio | -28.474 | -44.321 | -260.805 | -1,273.527 | -81.709 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -53.091 | -76.655 | -25.190 | -6.438 | -0.581 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 89.5% | ▲4.7% | ▲1.1% |
| Ebit Margin | -7.9% | ▼-2.3% | ▲332.1% |
| Ebitda Margin | -7.2% | ▼-2.1% | ▲326.4% |
| Operating Profit Margin | -10.1% | ▼-1.7% | ▲334.0% |
| Pretax Profit Margin | -14.9% | ▼-3.2% | ▲340.0% |
| Continuous Operations Profit Margin | -15.1% | ▼-3.4% | ▲339.9% |
| Net Profit Margin | -15.1% | ▼-3.4% | ▲339.9% |
| Bottom Line Profit Margin | -15.1% | ▼-3.4% | ▲339.9% |
| Current Ratio | 4.315 | ▼-0.265 | ▲0.585 |
| Quick Ratio | 4.115 | ▼-0.193 | ▲0.538 |
| Solvency Ratio | -0.175 | ▼-0.034 | ▲0.593 |
| Cash Ratio | 0.767 | ▼-0.067 | ▼-0.205 |
| Price To Earnings Ratio | -22.423 | ▲7.401 | ▼-6.338 |
| Price To Earnings Growth Ratio | -0.423 | ▼-1.112 | ▼-0.637 |
| Forward Price To Earnings Growth Ratio | -0.423 | ▼-1.112 | ▼-0.637 |
| Price To Earnings Diluted Ratio | -22.423 | ▲7.401 | ▼-6.338 |
| Price To Earnings Diluted Growth Ratio | -0.423 | ▼-1.112 | ▼-0.637 |
| Price To Book Ratio | 8.417 | ▲1.535 | ▲2.530 |
| Price To Sales Ratio | 3.450 | ▼-0.125 | ▼-4.145 |
| Price To Free Cash Flow Ratio | -31.955 | ▼-5.926 | ▼-15.900 |
| Price To Operating Cash Flow Ratio | -33.077 | ▼-6.462 | ▼-16.666 |
| Debt To Assets Ratio | 0.422 | ▲0.070 | ▲0.130 |
| Debt To Equity Ratio | 1.267 | ▲0.382 | ▲0.585 |
| Debt To Capital Ratio | 0.559 | ▲0.089 | ▲0.178 |
| Long Term Debt To Capital Ratio | 0.553 | ▲0.087 | ▲0.303 |
| Financial Leverage Ratio | 3.005 | ▲0.490 | ▲0.794 |
| Working Capital Turnover Ratio | 1.423 | ▲0.017 | ▲0.542 |
| Operating Cash Flow Ratio | -0.479 | ▲0.096 | ▲0.879 |
| Operating Cash Flow Sales Ratio | -0.104 | ▲0.030 | ▲3.378 |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | ▲0.013 | ▲0.020 |
| Debt Service Coverage Ratio | -1.009 | ▼-0.164 | ▲1.826 |
| Interest Coverage Ratio | -1.443 | ▼-0.052 | ▲9.920 |
| Short Term Operating Cash Flow Coverage Ratio | -28.724 | ▼-28.724 | ▼-21.509 |
| Operating Cash Flow Coverage Ratio | -0.201 | ▲0.091 | ▲1.273 |
| Capital Expenditure Coverage Ratio | -28.474 | ▲15.848 | ▲309.293 |
| Dividend Paid And Capex Coverage Ratio | -28.474 | ▲15.848 | ▲309.293 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -53.091 | ▲23.564 | ▼-20.700 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.41B | $1.19B | $1.36B | $452.3M | $114.6M | |
| Enterprise value | $1.55B | $1.28B | $1.39B | $392.6M | $87.7M | |
| EV / Sales | 3.80x | 3.84x | 11.20x | 7.53x | 8.69x | |
| EV / Op. cash flow | -36.46x | -28.59x | -15.54x | -5.61x | -0.57x | |
| EV / Free cash flow | -35.22x | -27.96x | -15.48x | -5.60x | -0.57x | |
| EV / EBITDA | -53.09x | -76.66x | -25.19x | -6.44x | -0.58x | |
| Net debt / EBITDA | -4.92x | -5.30x | -0.62x | 0.98x | 0.18x | |
| Current ratio | 4.32x | 4.58x | 4.88x | 2.34x | 2.53x | |
| Income quality | 0.69x | 1.15x | 1.36x | 1.04x | 0.96x | |
| Graham net-net | -$0 | $0 | $0 | $0 | $0 | |
| Tax burden | 101.6% | 100.7% | 100.8% | 100.0% | 100.0% | |
| Interest burden | 188.1% | 207.0% | 115.7% | 108.2% | 102.9% | |
| Working capital | $293.7M | $278.6M | $195.7M | $88.0M | $80.8M | |
| Invested capital | $300.7M | $282.5M | $202.3M | $98.5M | $95.9M | |
| Return on assets | -12.3% | -9.0% | -22.2% | -35.4% | -105.5% | |
| Operating ROA | -8.7% | -7.6% | -26.0% | -37.5% | -87.8% | |
| Return on tangible assets | -12.3% | -9.0% | -22.2% | -35.4% | -105.5% | |
| Return on equity | -36.9% | -22.6% | -39.6% | -68.3% | -191.4% | |
| Return on invested capital | -9.9% | -7.8% | -25.1% | -41.1% | -116.2% | |
| Return on capital employed | -9.9% | -7.8% | -25.6% | -51.2% | -159.0% | |
| Earnings yield | -4.4% | -3.3% | -4.9% | -14.9% | -138.0% | |
| Free cash flow yield | -3.1% | -3.8% | -6.6% | -15.5% | -134.7% | |
| Capex / Op. cash flow | -3.5% | -2.3% | -0.4% | -0.1% | -1.2% | |
| Capex / Depreciation | 48.8% | 49.0% | 26.6% | 4.8% | 129.6% | |
| Capex / Sales | 0.4% | 0.3% | 0.3% | 0.1% | 18.5% | |
| SG&A / Sales | 82.8% | 77.5% | 108.0% | 146.9% | 716.1% | |
| R&D / Sales | 16.8% | 15.7% | 28.6% | 67.5% | 902.6% | |
| Stock comp / Sales | 12.0% | 11.2% | 10.9% | 20.6% | 119.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 64d | 63d | 65d | 54d | 18d | |
| Days payables outstanding | 165d | 116d | 228d | 963d | 1561d | |
| Operating cycle | 216d | 216d | 320d | 345d | 18d | |
| Cash conversion cycle | 52d | 100d | 91d | -618d | -1543d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-18 Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX) Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations
- 2026-08-17 ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX) Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company''s s
- 2026-08-17 ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX) NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company''s second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The damage came alongside numbers the Company itself called records. Arde.
- 2026-08-14 ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx /PRNewswire/ -- Payer coverage restrictions allegedly cost Ardelyx (NASDAQ: ARDX) shareholders roughly 18% of their investment on August 7, 2026, when the
- 2026-08-13 Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) Ardelyx Investigation Notice: Levi and Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) PR Newswire
- 2026-08-13 Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and a loss of approximately $(0.07) per share -- both below consensus estimates.
- 2026-08-12 Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX''s Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.
- 2026-08-07 Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
- 2026-08-07 New Strong Sell Stocks for August 7th ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.
- 2026-08-06 Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.